摘要
目的探讨依帕司他联合甲钴胺用于治疗糖尿病周围神经病变(DPN)患者的临床效果。方法选取2016年1月至2019年9月山西省大同市第五人民医院收治的57例DPN患者作为研究对象,随机分为依帕司他组(19例,单独口服依帕司他治疗)、甲钴胺组(19例,单独口服甲钴胺治疗)和联合用药组(19例,采用依帕司他联合甲钴胺治疗),比较3组的治疗效果。结果治疗后,3组神经传导速度、神经病变主觉症状问卷(TSS)评分显著改善,且联合用药组神经传导速度、TSS评分显著优于依帕司他组和甲钴胺组,差异有统计学意义(P<0.05);治疗后,3组空腹血糖、糖化血红蛋白明显低于治疗前,差异有统计学意义(P<0.05),但空腹血糖、糖化血红蛋白组间比较差异无统计学意义(P>0.05);治疗后3组8-异前列腺素F2α(8-iso-PGF2α)显著降低,且联合用药组8-iso-PGF2α显著低于依帕司他组和甲钴胺组,差异有统计学意义(P<0.05);治疗前后3组白细胞介素-6(IL-6)比较差异无统计学意义(P>0.05);3组不良反应发生率比较差异无统计学意义(P>0.05)。结论与单独用药比较,依帕司他联合甲钴胺用于治疗DPN改善患者神经传导速度、自觉症状及氧化应激方面效果更佳,且并未增加不良反应发生率,安全有效。
Objective To explore the clinical effects of epastat combined with mecobalamin in the treatment of the patients with diabetic peripheral neuropathy(DPN). Methods A total of fifty-seven DPN patients treated in the Fifth People’s Hospital of Daton in Shannxi Province from January 2016 to September 2019 were selected as the research objects and were randomly divided into an epastat group(n=19, epastat), a mecobalamin group(n=19, mecobalamin) and a combined treatment group(n=19, epastat combined with mecobalamin). The curative effects of the three groups were compared. Results After treatment, the nerve conduction velocity and neuropathy subjective symptoms(TSS) questionnaire were significantly improved in the three groups, and the nerve conduction velocity and TSS score in the combined treatment group were significantly superior to those in the epastat group and mecobalamin group and the difference was statistically significant(P<0.05). After treatment, fasting blood glucose and glycosylated hemoglobin were significantly improved in the three groups and the difference was statistically significant(P<0.05), However, there was no significant difference between fasting blood glucose and glycosylated hemoglobin groups(P>0.05). After treatment, the 3-group 8-iso-prostaglandin F2α(8-iso-PGF2α) was significantly reduced, and the 8-iso-PGF2α in the combination group was significantly lower than the epalrestat group and the mecobalamin group, the difference was statistically significant(P<0.05);there was no statistically significant difference in interleukin-6(IL-6) between the three groups before and after treatment(P>0.05);and there was no significant difference in the incidence of adverse reactions among the three groups(P>0.05). Conclusion Compared with single drug, ipastat combined with mecobalamin is more effective in the treatment of diabetic peripheral neuropathy in improving nerve conduction velocity, conscious symptoms and oxidative stress, and does not increase the incidence of adverse reactions. It is safe and effective.
作者
田沛文
佘雪梅
TIAN Pei-Wen;SHE Xue-Mei(Department of Endocrinology,the Fifth People's Hospital of Daton in Shannxi Province,Daton 037006,China)
出处
《中国药物经济学》
2020年第9期68-71,共4页
China Journal of Pharmaceutical Economics
作者简介
通信作者:佘雪梅,E-mail:835367750@qq.com。
